Table 3:

Measurement of Lung Cancer Screening Participants in the OaSiS Trial (Baseline Accrual Goal, n=1,200; 50 participants for each of the 24 participating sites). To date, 1,053 participants have enrolled in the study (88%).

Baseline (In-Person): Demographics (e.,g, sex, age, race, ethnicity, education, marital status, income, insurance); Health Status; Prior History of Cancer; Perceived Lung Cancer Risk and Worry; Perceived Benefit of Quitting; Quit Behavior (Readiness and Confidence to Quit, Prior Quit attempts); Self-Reported Smoking Status (Past 7 and 30 days; Nicotine Dependence (Fagerstrom); Number of Pack Years Smoked; Number of Cigarettes per Day; Other Tobacco Products Used (e.g., e-cigarettes)

• 14 Days (Telephone): Scope and Satisfaction with Smoking Cessation Services Received during and after LDCT (e.g., asked about tobacco, assessed readiness to quit, cessation support services received; follow-up cessation services provided after LDCT screening); Receipt and Understanding of Lung Screening Results; Smoking Status (Past 7 and 30 days)

• 3 Months (Telephone): Scope and Satisfaction with Smoking Cessation Services Received during and after LDCT (e.g., asked about tobacco, assessed readiness to quit, cessation support services received; follow-up cessation services provided after LDCT screening); Lung Cancer Risk and Worry; Perceived Benefits of Quitting; LungRads Score; Lung Screening Impact on Tobacco Use Behavior; Smoking Status (Past 7 and 30 days; Nicotine Dependence); Number of Pack Years Smoked; Number of Cigarettes per Day; Other Tobacco Products Used (e.g., e-cigarettes)

• 6 Months (Telephone): Lung Cancer Risk and Worry; Perceived Benefits of Quitting; Changes in Demographics (e.g., marital status); Lung Screening Impact on Tobacco Use Behavior; Smoking Status (Past 7 and 30 days; Nicotine Dependence

• Biochemical Validation of Self-Reported Smoking Status: Mailed Salivary Cotinine Kit